Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – What’s Next?

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) gapped down before the market opened on Friday . The stock had previously closed at $22.42, but opened at $21.62. Chugai Pharmaceutical shares last traded at $21.42, with a volume of 3,755 shares changing hands.

Wall Street Analyst Weigh In

CHGCY has been the topic of a number of research reports. The Goldman Sachs Group upgraded Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a report on Monday, June 15th. UBS Group cut Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Finally, Zacks Research raised Chugai Pharmaceutical to a “hold” rating in a research note on Friday, May 29th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy”.

Chugai Pharmaceutical Stock Performance

The company has a 50-day moving average of $22.60 and a 200-day moving average of $25.90. The stock has a market capitalization of $71.11 billion, a price-to-earnings ratio of 23.48 and a beta of 0.60.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its quarterly earnings results on Friday, July 24th. The company reported $0.22 earnings per share for the quarter. Chugai Pharmaceutical had a return on equity of 23.71% and a net margin of 35.09%.The company had revenue of $2.14 billion during the quarter, compared to the consensus estimate of $2.38 billion. As a group, analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 earnings per share for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.